Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen : Every Patient Counts, Every Story Matters

11/29/2021 | 07:12pm EST

In 2016, Jeff Carpenter learned that he had both lung cancer and a brain tumor. Ten days later, doctors successfully removed his brain tumor, but told Jeff that because of his lung cancer he likely only had three to six months to live.

Jeff's oncologist Dr. Ravi Salgia of City of Hope, gave Jeff the news that his latest PET scan showed no evidence of lung cancer in January 2019. Recently, Jeff and Dr. Salgia reflected on the journey they went through together-from their first meeting in Jeff's hospital room after his brain surgery to the day he learned he is cancer-free.

"We hold hands to go through this journey together and you truly represent that miracle," Dr. Salgia said. Their story is part of Every Patient Counts, Every Story Matters - an Amgen sponsorship with the non-profit organization StoryCorps to raise awareness about different types of cancer through the sharing of personal stories.

StoryCorps' mission is to preserve and share humanity's stories in order to build connections between people and create a more just and compassionate world. With permission, the conversations that StoryCorps facilitates and record are archived at the Library of Congress.

Amgen and StoryCorps have worked together for more than five years to bring together patients, caregivers, nurses, doctors, and others affected by cancer to reflect on their most poignant moments. Jeff and Dr. Salgia's story is one of several recorded with City of Hope earlier this year.

November is Lung Cancer Awareness Month-a time when sharing and listening to inspirational stories can help support those in the lung cancer community and raise awareness about the impact of this disease.

Listen to an excerpt of the conversation between Jeff and his doctor below.

To hear more stories, visit Amgen's Every Patient Counts, Every Story Matters playlist on YouTube and follow Amgen Oncology's Twitter and LinkedIn channels to stay up to date on our latest.

Disclaimer

Amgen Inc. published this content on 29 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 November 2021 00:10:10 UTC.


ę Publicnow 2021
All news about AMGEN INC.
01/21Amgen - LUMAKRAS (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUT..
AQ
01/20AMGEN PLUGS IN : Electric Vehicle Pilot Program Advances Carbon Neutrality Goal
PU
01/20Amgen Secures Japanese Approval of Non-Small Cell Lung Cancer Drug Lumakras
MT
01/20Amgen Inc.'s LUMAKRAS Receives Approval in Japan for Patients with KRAS G12C-Mutated Ad..
CI
01/20"SHOW MORE OF YOU" : Amgen V. Sandoz, Battling It Out On Amgen's Otezla« Drug
AQ
01/19FDA Clears CytomX's Investigational New Drug Application for CX-904 in Advanced Solid T..
MT
01/18Medicenna Therapeutics up 12.7% in US Trade, Details Management Change, Appoints Develo..
MT
01/14AMGEN : Teneobio Acquisition Adds Talent and New Types of Antibodies to Amgen
PU
01/13BridgeBio to Study BBP-398 With Amgen's Lumakras in Solid Tumors
DJ
01/13BridgeBio Pharma, Amgen Team Up to Evaluate Combination Treatment for Advanced Solid Tu..
MT
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 017 M - -
Net income 2021 5 570 M - -
Net Debt 2021 21 988 M - -
P/E ratio 2021 22,0x
Yield 2021 3,11%
Capitalization 126 B 126 B -
EV / Sales 2021 5,69x
EV / Sales 2022 5,37x
Nbr of Employees 24 300
Free-Float -
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 224,00 $
Average target price 239,82 $
Spread / Average Target 7,06%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-0.43%126 172
JOHNSON & JOHNSON-0.28%449 095
ROCHE HOLDING AG-6.46%307 637
PFIZER, INC.-9.62%299 559
ABBVIE INC.0.42%240 379
NOVO NORDISK A/S-12.29%219 960